Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1397-1402

  Bethge, W A ^a   Von Harsdorf, S ^b   Bornhauser, M ^c   Federmann, B ^a   Stelljes, M ^d   Trenschel, R ^e   Baurmann, H ^f   Dittmann, H ^g   Faul, C ^a   Vogel, W ^a   Kanz, L ^a   Bunjes, D ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

allogeneic hematopoietic cell transplantation; dose escalation; non Hodgkin lymphoma; radioimmunotherapy; reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SURVIVAL TIME; VEIN OCCLUSION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YTTRIUM RADIOISOTOPES;

EID: 84869087675     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.62     Document Type: Article

References (39)

1. Hamadani M, Benson Jr. DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547-553.
2. Peniket AJ, Ruiz De Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678. (Pubitemid 36553477)
3. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant 2004; 34: 929-938. (Pubitemid 39600108)
4. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-4205. (Pubitemid 27484077)
5. Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 2000; 27: 78-81. (Pubitemid 30422440)
6. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871. (Pubitemid 39620131)
7. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463. (Pubitemid 34525730)
8. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213-5218.
9. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M et al. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 2009; 115: 4533-4539.
10. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
11. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495. (Pubitemid 28107956)
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
13. Sullivan KM. Graft-versus-host-disease. In: Blume KG, Forman SJ, Appelbaum FR eds. Thomas' Hematopoietic Cell Transplantation. Blackwell Science Ltd, Oxford: UK, 2004, pp 635-664.
14. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2011.
15. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387. (Pubitemid 47202424)
16. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726.
17. Tennvall J, Fischer M, Bischof DA, Bombardieri E, Bodei L, Giammarile F et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2007; 34: 616-622. (Pubitemid 46427010)
18. +) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
19. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269. (Pubitemid 34831524)
20. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629-636.
21. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54-58. (Pubitemid 47026818)
22. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465-474. (Pubitemid 39586026)
23. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 90-95.
24. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
25. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461-467. (Pubitemid 46224222)
26. Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquieres H, Bouabdallah K et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory lowgrade CD20-positive B-cell lymphoma. A GELA Phase II Prospective Study. Clin Lymphoma Myeloma Leuk 2011; 11: 212-218.
27. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 1653-1659.
28. Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008; 26: 5175-5182.
29. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant 2008; 41: 355-361. (Pubitemid 351330730)
30. Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomabtiuxetan. Leuk Lymphoma 2006; 47: 59-63. (Pubitemid 43101725)
31. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 2010; 116: 1795-1802.
32. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG et al. 90Y-ibritumomab tiuxetan, fludarabine, and TBI based non-myeloablative allogeneic transplant conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118: 1132-1139.
33. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777. (Pubitemid 30456759)
34. Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A et al. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2009; 36: 1745-1757.
35. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-hodgkin's lymphoma. J Clin Oncol 2008; 26: 211-217.
36. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
37. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T cell antibodies on outcomes of reduced intensity allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970.
38. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-celldepleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695-3700.
39. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395-403.